The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Disclosed herein are anti-IgE antibodies having low binding affinity to human IgE and compositions and methods thereof.

The present invention is directed to methods for using particles (e.g, microparticulate, nanoparticulate; magnetic, non-magnetic) comprising surfaces comprising capture moieties as described herein, to remove an interference as described herein, or enrich biomarkers, especially antibodies, prior to a diagnostic test, or to be isolated and used for prophylactic or therapeutic purposes.

The present invention is directed to methods for using particles (e.g, microparticulate, nanoparticulate; magnetic, non-magnetic) comprising surfaces comprising capture moieties as described herein, to remove an interference as described herein, or enrich biomarkers, especially antibodies, prior to a diagnostic test, or to be isolated and used for prophylactic or therapeutic purposes.

The present disclosure relates to methods for modifying the course of a disease or disorder involving Treg cells dysfunctioning, in particular in patients having an allergic disease or condition.

The technology described herein is directed to structural analysis, particularly of small proteins via cryo-EM.

The application provides a method of identifying or monitoring a plasma cell associated disease, comprising purifying immunoglobulin free light chains (FLCs) from a sample from a subject with anti-FLC specific antibodies or fragments thereof and subjecting the purified sample to a mass spectrometry technique to identify the presence of one or more peaks corresponding to one or more monoclonal FLCs in the sample.

The application provides a method of identifying or monitoring a plasma cell associated disease, comprising purifying immunoglobulin free light chains (FLCs) from a sample from a subject with anti-FLC specific antibodies or fragments thereof and subjecting the purified sample to a mass spectrometry technique to identify the presence of one or more peaks corresponding to one or more monoclonal FLCs in the sample.

The present invention provides a protein construct comprising: a) at least two monomers each of which comprises a C-type lectin domain of CD23, wherein each monomer can bind to IgE; and b) an entity which can bind to the neonatal Fc receptor (FcRn); wherein said protein construct comprises a linker, and wherein said linker is used to link said monomer comprising a C-type lectin domain of CD23 to said entity which can bind to FcRn. Therapeutic uses of the constructs, for example in anti-IgE therapy or for use in the treatment or prevention of an IgE related disease or condition are also provided.

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V.sub.H, V.sub.L, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.